Patterns of progression in XXXX following anti-VEGF therapy: perceptions and evidence.

@entity1 @entity851 @entity5 @entity1493 @entity11 @entity463
Antiangiogenic treatment has recently become an integral part of modern @entity5 therapy targeting the vasculature of numerous aggressive @entity5 including @entity463 . There is preclinical evidence that antiangiogenic therapies promote @entity11 cell invasiveness. In clinical series, upon progression on antiangiogenic therapy with the vascular endothelial growth factor-directed antibody bevacizumab ( @entity1493 ), @entity463 has been reported to display a more infiltrative pattern of recurrence. This distant spread at recurrence or progression and a @entity851 pattern is best detectable on fluid-attenuated inversion recovery MRI. The frequency of up to 20% to 30% of such a pattern in @entity1493 -treated @entity1 is higher than expected to occur without @entity1493 . Older reports and common clinical knowledge estimate the frequency of diffuse or distant spread in recurrent @entity463 at 10%. This observation stimulated two streams of research. One is to overcome this often insidious adverse effect of antiangiogenic treatment, to optimize antiangiogenic therapies and to face this major challenge, integrating antiangiogenic with anti-invasive mechanisms into one combined treatment concept. The second is questioning a specific property of antiangiogenic therapy to induce diffuse or distant spread. Here, alternative hypotheses of increased awareness and better imaging as well as invasiveness being part of the natural course of the disease have been tested. Without doubt, migration and invasiveness are major obstacles to successful @entity11 therapy, notably local therapies, both in the natural course of the disease and in the concept of "evasive resistance." However, clinical analyses of case series, matched pairs analyses, and follow-up on the BRAIN trial (A Study to Evaluate Bevacizumab Alone or in Combination with Irinotecan for Treatment of @entity463 ), which led to accelerated approval of @entity1493 for recurrent @entity463 in the United States, have not supported a specific propensity of @entity1493 to induce diffuse growth or distant spread at recurrence.
